{"id":45902,"date":"2025-11-05T21:10:47","date_gmt":"2025-11-05T13:10:47","guid":{"rendered":"https:\/\/flcube.com\/?p=45902"},"modified":"2025-11-05T21:10:48","modified_gmt":"2025-11-05T13:10:48","slug":"4d-molecular-transfers-asia%e2%80%91pacific-gene%e2%80%91therapy-rights-to-otsuka-for-85-m-cash","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45902","title":{"rendered":"4D\u202fMolecular Transfers Asia\u2011Pacific Gene\u2011Therapy Rights to Otsuka for $85\u202fM Cash"},"content":{"rendered":"\n<p><strong>4D Molecular Therapeutics (4DMT)<\/strong> sold the Asia\u2011Pacific rights to its eye\u2011gene therapy <strong>4D\u2011150<\/strong> to <strong>Otsuka Pharmaceutical<\/strong>. The transaction yielded an upfront <strong>USD\u202f85\u202fmillion<\/strong> cash payment, earmarked for the therapy\u2019s Phase\u2011III development. In a reciprocal licensing arrangement, Otsuka will seek to develop and commercialise 4D\u2011150 for retinal vascular diseases\u2014wet age\u2011related macular degeneration (wet\u202fAMD) and diabetic macular edema (DME)\u2014across Japan, China, Australia, and the broader Asia\u2011Pacific region.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-terms-amp-milestone-expectations\">Deal Terms &amp; Milestone Expectations<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Up\u2011front cash<\/strong><\/td><td>USD\u202f85\u202fmillion<\/td><\/tr><tr><td><strong>Regional rights<\/strong><\/td><td>Japan, China, Australia, and other APAC markets<\/td><\/tr><tr><td><strong>Cost\u2011share commitment<\/strong><\/td><td>Minimum USD\u202f50\u202fmillion over three years<\/td><\/tr><tr><td><strong>Revenue upside<\/strong><\/td><td>Up to USD\u202f336\u202fmillion in regulatory &amp; commercial milestone payments<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered double\u2011digit royalty rates<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Should 4D\u2011150 clear regulatory milestones and achieve commercial launch, Otsuka could unlock the full milestone package and ongoing royalties that reflect the therapy\u2019s potential to disrupt the market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-4d-150-a-sustained-release-anti-vegf-gene-vaccine\">4D\u2011150: A Sustained\u2011Release Anti\u2011VEGF Gene Vaccine<\/h2>\n\n\n\n<p>4D\u2011150 encodes <strong>aflibercept<\/strong> and a VEGF\u2011C\u2011inhibiting sequence, delivering sustained anti\u2011VEGF activity while obviating frequent intravitreal injections. The platform leverages viral vector technology to provide a long\u2011lasting therapeutic effect, addressing a key unmet need in chronic retinal disease management.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-supporting-data\">Supporting Data<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase\u202fII (60\u202fweeks)<\/strong> results disclosed three months prior to the deal: patients receiving the Phase\u2011III dose of 4D\u2011150 experienced a <strong>78\u202f%<\/strong> reduction in supplemental injections versus the projected on\u2011label aflibercept 2\u202fmg regimen.<\/li>\n<\/ul>\n\n\n\n<p>These data bolster confidence in 4D\u2011150\u2019s clinical efficacy, underpinning the $85\u202fmillion upfront valuation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>4DMT<\/strong> secures the capital and APAC partnership needed to accelerate its Phase\u2011III programme.<\/li>\n\n\n\n<li><strong>Otsuka<\/strong> expands its ophthalmology pipeline with a compelling, non\u2011injection gene\u2011therapy candidate that could tap into high\u2011growth markets in Asia\u2011Pacific.<\/li>\n<\/ul>\n\n\n\n<p>The transaction exemplifies a growing trend where early\u2011stage biotech entities partner with regional manufacturers to leverage local expertise and secure development funding.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>4D Molecular Therapeutics (4DMT) sold the Asia\u2011Pacific rights to its eye\u2011gene therapy 4D\u2011150 to Otsuka&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45904,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4430,66,44,439],"class_list":["post-45902","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-4d-molecular-therapeutics","tag-gene-therapy","tag-ophthalmology","tag-otsuka-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>4D\u202fMolecular Transfers Asia\u2011Pacific Gene\u2011Therapy Rights to Otsuka for $85\u202fM Cash - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"4D Molecular Therapeutics (4DMT) sold the Asia\u2011Pacific rights to its eye\u2011gene therapy 4D\u2011150 to Otsuka Pharmaceutical. The transaction yielded an upfront USD\u202f85\u202fmillion cash payment, earmarked for the therapy\u2019s Phase\u2011III development. In a reciprocal licensing arrangement, Otsuka will seek to develop and commercialise 4D\u2011150 for retinal vascular diseases\u2014wet age\u2011related macular degeneration (wet\u202fAMD) and diabetic macular edema (DME)\u2014across Japan, China, Australia, and the broader Asia\u2011Pacific region.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45902\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"4D\u202fMolecular Transfers Asia\u2011Pacific Gene\u2011Therapy Rights to Otsuka for $85\u202fM Cash\" \/>\n<meta property=\"og:description\" content=\"4D Molecular Therapeutics (4DMT) sold the Asia\u2011Pacific rights to its eye\u2011gene therapy 4D\u2011150 to Otsuka Pharmaceutical. The transaction yielded an upfront USD\u202f85\u202fmillion cash payment, earmarked for the therapy\u2019s Phase\u2011III development. In a reciprocal licensing arrangement, Otsuka will seek to develop and commercialise 4D\u2011150 for retinal vascular diseases\u2014wet age\u2011related macular degeneration (wet\u202fAMD) and diabetic macular edema (DME)\u2014across Japan, China, Australia, and the broader Asia\u2011Pacific region.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45902\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-05T13:10:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-05T13:10:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0502-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45902#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45902\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"4D\u202fMolecular Transfers Asia\u2011Pacific Gene\u2011Therapy Rights to Otsuka for $85\u202fM Cash\",\"datePublished\":\"2025-11-05T13:10:47+00:00\",\"dateModified\":\"2025-11-05T13:10:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45902\"},\"wordCount\":329,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45902#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0502-1.webp\",\"keywords\":[\"4D Molecular Therapeutics\",\"Gene therapy\",\"Ophthalmology\",\"Otsuka Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45902#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45902\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45902\",\"name\":\"4D\u202fMolecular Transfers Asia\u2011Pacific Gene\u2011Therapy Rights to Otsuka for $85\u202fM Cash - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45902#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45902#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0502-1.webp\",\"datePublished\":\"2025-11-05T13:10:47+00:00\",\"dateModified\":\"2025-11-05T13:10:48+00:00\",\"description\":\"4D Molecular Therapeutics (4DMT) sold the Asia\u2011Pacific rights to its eye\u2011gene therapy 4D\u2011150 to Otsuka Pharmaceutical. The transaction yielded an upfront USD\u202f85\u202fmillion cash payment, earmarked for the therapy\u2019s Phase\u2011III development. In a reciprocal licensing arrangement, Otsuka will seek to develop and commercialise 4D\u2011150 for retinal vascular diseases\u2014wet age\u2011related macular degeneration (wet\u202fAMD) and diabetic macular edema (DME)\u2014across Japan, China, Australia, and the broader Asia\u2011Pacific region.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45902#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45902\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45902#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0502-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0502-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"4D\u202fMolecular Transfers Asia\u2011Pacific Gene\u2011Therapy Rights to Otsuka for $85\u202fM Cash\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45902#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"4D\u202fMolecular Transfers Asia\u2011Pacific Gene\u2011Therapy Rights to Otsuka for $85\u202fM Cash\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"4D\u202fMolecular Transfers Asia\u2011Pacific Gene\u2011Therapy Rights to Otsuka for $85\u202fM Cash - Insight, China&#039;s Pharmaceutical Industry","description":"4D Molecular Therapeutics (4DMT) sold the Asia\u2011Pacific rights to its eye\u2011gene therapy 4D\u2011150 to Otsuka Pharmaceutical. The transaction yielded an upfront USD\u202f85\u202fmillion cash payment, earmarked for the therapy\u2019s Phase\u2011III development. In a reciprocal licensing arrangement, Otsuka will seek to develop and commercialise 4D\u2011150 for retinal vascular diseases\u2014wet age\u2011related macular degeneration (wet\u202fAMD) and diabetic macular edema (DME)\u2014across Japan, China, Australia, and the broader Asia\u2011Pacific region.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45902","og_locale":"en_US","og_type":"article","og_title":"4D\u202fMolecular Transfers Asia\u2011Pacific Gene\u2011Therapy Rights to Otsuka for $85\u202fM Cash","og_description":"4D Molecular Therapeutics (4DMT) sold the Asia\u2011Pacific rights to its eye\u2011gene therapy 4D\u2011150 to Otsuka Pharmaceutical. The transaction yielded an upfront USD\u202f85\u202fmillion cash payment, earmarked for the therapy\u2019s Phase\u2011III development. In a reciprocal licensing arrangement, Otsuka will seek to develop and commercialise 4D\u2011150 for retinal vascular diseases\u2014wet age\u2011related macular degeneration (wet\u202fAMD) and diabetic macular edema (DME)\u2014across Japan, China, Australia, and the broader Asia\u2011Pacific region.","og_url":"https:\/\/flcube.com\/?p=45902","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-05T13:10:47+00:00","article_modified_time":"2025-11-05T13:10:48+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0502-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45902#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45902"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"4D\u202fMolecular Transfers Asia\u2011Pacific Gene\u2011Therapy Rights to Otsuka for $85\u202fM Cash","datePublished":"2025-11-05T13:10:47+00:00","dateModified":"2025-11-05T13:10:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45902"},"wordCount":329,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45902#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0502-1.webp","keywords":["4D Molecular Therapeutics","Gene therapy","Ophthalmology","Otsuka Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45902#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45902","url":"https:\/\/flcube.com\/?p=45902","name":"4D\u202fMolecular Transfers Asia\u2011Pacific Gene\u2011Therapy Rights to Otsuka for $85\u202fM Cash - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45902#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45902#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0502-1.webp","datePublished":"2025-11-05T13:10:47+00:00","dateModified":"2025-11-05T13:10:48+00:00","description":"4D Molecular Therapeutics (4DMT) sold the Asia\u2011Pacific rights to its eye\u2011gene therapy 4D\u2011150 to Otsuka Pharmaceutical. The transaction yielded an upfront USD\u202f85\u202fmillion cash payment, earmarked for the therapy\u2019s Phase\u2011III development. In a reciprocal licensing arrangement, Otsuka will seek to develop and commercialise 4D\u2011150 for retinal vascular diseases\u2014wet age\u2011related macular degeneration (wet\u202fAMD) and diabetic macular edema (DME)\u2014across Japan, China, Australia, and the broader Asia\u2011Pacific region.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45902#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45902"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45902#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0502-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0502-1.webp","width":1080,"height":608,"caption":"4D\u202fMolecular Transfers Asia\u2011Pacific Gene\u2011Therapy Rights to Otsuka for $85\u202fM Cash"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45902#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"4D\u202fMolecular Transfers Asia\u2011Pacific Gene\u2011Therapy Rights to Otsuka for $85\u202fM Cash"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0502-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45902","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45902"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45902\/revisions"}],"predecessor-version":[{"id":45905,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45902\/revisions\/45905"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45904"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45902"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45902"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45902"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}